Encorafenib Plus Binimetinib for BRAF-Mutated Metastatic Melanoma: 7-Year Follow-Up Data From the COLUMBUS Trial
The 7-year follow-up data for encorafenib/binimetinib showing that around 21% of patients remained progression-free supports BRAF/MEK inhibition as a later treatment option after immunotherapy failure, but doctors are reluctant to stop BRAF/MEK inhibitors given lack of data, even in those patients doing well long-term on the medications with minimal toxicity.
EP: 1.The Role of Biomarker Testing in the Management of Metastatic Melanoma
EP: 2.Best Practices for Biomarker Testing in Metastatic Melanoma
EP: 3.Differences Between Community and Academic Settings Regarding Biomarker Testing Practices in Metastatic Melanoma
EP: 4.Treatment Options for Patients With Metastatic Melanoma With a BRAF Mutation
EP: 5.Factors Influencing Treatment Decision-Making In Patients With BRAF-Mutated Metastatic Melanoma
EP: 6.Frontline Treatment Options for Patients With BRAF-Mutated Metastatic Melanoma
EP: 7.Common Adverse Effects Seen With BRAF/MEK Inhibitor Therapy in Patients With BRAF-Mutated Metastatic Melanoma
EP: 8.Choosing Between Available Combination BRAF/MEK Inhibitor Options for Patients With BRAF-Mutated Metastatic Melanoma
Now Viewing
EP: 9.Encorafenib Plus Binimetinib for BRAF-Mutated Metastatic Melanoma: 7-Year Follow-Up Data From the COLUMBUS Trial
EP: 10.Efficacy and Safety of Rechallenge With BRAF/MEK Inhibitors in Patients With BRAF-Mutated Metastatic Melanoma
EP: 11.Treatment Approaches For Patients With BRAF-Mutated Melanoma and Asymptomatic Brain Metastases
EP: 12.Treatment Approaches For Patients With BRAF-Mutated Melanoma and Symptomatic Brain Metastases
EP: 13.Key Data on Combination Immunotherapies in BRAF-Mutated Melanoma with Brain Metastases
EP: 14.The Future of Metastatic and Unresectable Melanoma Treatment
Related Videos
Related Content
